The US Food and Drug Administration has granted clearance to PearlBone Putty 1600, a bone repair material made from sustainably sourced pearl shells, making it the first replacement bone graft material derived from nacre, or mother-of-pearl.
The clearance, granted under the FDA's 510(k) process, allows the material to be marketed and sold for use in bone fracture repair. The product was developed by a team that includes a regenerative biologist from the University of Western Australia, who developed a chemical reaction that converts the calcium carbonate in nacre into calcium phosphate, the mineral component of human bone, within 24 hours.
"We developed and patented a technology that converts nacre, the mineralized structure of pearl shell, into a bone mineral matrix composite," said regenerative biologist and team member Minghao Zheng.
Current approaches to bone grafting include taking bone from elsewhere in a patient's body, which offers a good match but can cause pain and extend surgery time, or using artificial substitutes that may not integrate as well and can have limitations in strength and absorption. PearlBone is designed to fill gaps while a bone heals, encouraging natural bone cells to grow and eventually being replaced by normal bone. Under the FDA's terms, it cannot be used in situations where the graft would need to be "intrinsic to the stability" of the bone overall, and could be used alongside fittings such as plates or screws.
The material is made from shells of the Pinctada maxima pearl oyster, a by-product of the pearl farming industry that would otherwise be discarded, making the process sustainable. In a study published in the journal Materials & Design, the researchers reported that the nacre-based calcium orthophosphate composite demonstrated accelerated biodegradation and osteostimulative properties, which they described as making it a promising bone substitute for effective bone regeneration.
The biotech company behind PearlBone, Marine Biomedical, must still work with US partners to manufacture and sell the product to clinical and commercial partners. "The FDA approval reflects years of scientific research and extraordinary dedication," said CEO Rolee Kumar.
The US orthopaedic products market is estimated to be worth $1.1 billion annually, pointing to significant commercial potential for the new material.
Analysis
Why This Matters
- PearlBone offers a new alternative that could reduce the need for harvesting a patient's own bone, potentially shortening surgery and recovery.
- The material turns a waste product from pearl farming into a valuable medical resource, highlighting a sustainable approach.
- The US market for orthopaedic products exceeds $1 billion, giving the innovation strong commercial prospects that could support further development.
Background
Bone grafts are commonly used to repair fractures and fill defects from injury or surgery. Current standard options include autografts, which use bone taken from the patient, and allografts from donors or synthetic substitutes. PearlBone is a new category derived from nacre, the inner layer of oyster shells, converted through a patented chemical process into a bone mineral composite.
What to Watch
- Manufacturing and distribution: Marine Biomedical must establish US partnerships to bring the product to market.
- Regulatory path in other countries: Future approvals could expand access beyond the US.
- Clinical uptake: Surgeon adoption and long-term outcomes will determine whether PearlBone becomes a widely used option.
Checked
12 claims in this story checked against 1 source: 11 supported.
Show each claim
- SupportedThe FDA cleared PearlBone Putty 1600 as the first replacement bone graft material made from pearl shells.ScienceAlert: “PearlBone Putty 1600, made from sustainably sourced pearl shells, was just given 510(k) clearance by the country's Food and Drug Administration (FDA). That means PearlBone can now be marketed and sold in the US as a substance used for repairing bone fractures. It's the first replacement bone graft material to be made from nacre”
- SupportedPearlBone Putty 1600, derived from mother-of-pearl, could offer an alternative to existing bone graft options.ScienceAlert: “Now it's another step towards being put to use in hospitals and clinics, PearlBone promises to be a valuable alternative to current approaches to bone grafts.”
- SupportedThe FDA’s 510(k) clearance allows PearlBone to be marketed and sold in the US for repairing bone fractures.ScienceAlert: “PearlBone Putty 1600, made from sustainably sourced pearl shells, was just given 510(k) clearance by the country's Food and Drug Administration (FDA). That means PearlBone can now be marketed and sold in the US as a substance used for repairing bone fractures.”
- SupportedA team including UWA regenerative biologist Minghao Zheng developed a reaction that converts nacre’s calcium carbonate into calcium phosphate in 24 hours.ScienceAlert: “The research team behind PearlBone developed a chemical reaction that turns the calcium carbonate of nacre into the calcium phosphate of human bone, ready for grafting, in the span of 24 hours.”
- SupportedMinghao Zheng said: “We developed and patented a technology that converts nacre, the mineralized structure of pearl shell, into a bone mineral matrix composite.”ScienceAlert: ““We developed and patented a technology that converts nacre, the mineralized structure of pearl shell, into a bone mineral matrix composite,” says regenerative biologist Minghao Zheng from the University of Western Australia, one of the team behind PearlBone.”
- SupportedTaking bone from elsewhere in a patient’s body can provide a good match but cause pain and extend surgery time; artificial substitutes may not take as well and can have strength and absorption limitations.ScienceAlert: “The best existing option is to take bone from elsewhere in a patient's body, which guarantees a good match but can cause pain and extended surgery times. Other artificial bone substitutes are also available, but don't always take as well, and can be limited in terms of strength and absorption rates.”
- SupportedPearlBone is designed to fill gaps as a bone heals, encourage natural bone cells to grow, and eventually be replaced by normal bone.ScienceAlert: “In other words, it's used to fill gaps while a bone heals, potentially alongside other fittings like plates or screws. One of the cleverest aspects of the material is the way it encourages natural bone cells to fill the gaps, supporting bone regrowth through a carefully calibrated structure, and then eventually being replaced by normal bone.”
- SupportedThe graft cannot be used where it would be intrinsic to the overall stability of the bone, and may be used with plates or screws.ScienceAlert: “However, as the FDA requirements clarify that the grafts can't be “intrinsic to the stability” of the bone overall. In other words, it's used to fill gaps while a bone heals, potentially alongside other fittings like plates or screws.”
- SupportedThe material uses Pinctada maxima pearl oyster shells, a pearl-farming by-product that would otherwise be discarded.ScienceAlert: “Using shells from the Pinctada maxima pearl oyster, found off the coast of Western Australia, the process requires grinding the shells into a powder and mixing the powder with a calcium phosphate salt and water. The operation is sustainable too, because it uses existing by-products of the pearl farming industry that would otherwise be discarded”
- SupportedA Materials & Design study reported accelerated biodegradation and osteostimulative properties, describing the composite as a promising bone substitute for regeneration.ScienceAlert: ““Overall, our data showed that NCOC produced through self-setting reactions, presents advantages such as accelerated biodegradation and osteostimulative properties, making it a promising bone substitute for effective bone regeneration,” write the researchers in their published paper.”
- SupportedMarine Biomedical still needs to work with US partners to manufacture and sell PearlBone to clinical and commercial partners.ScienceAlert: “The biotech company responsible for PearlBone, Marine Biomedical, still needs to work with partners in the US to get it manufactured and sold to clinical and commercial partners.”
- Partly supportedCEO Rolee Kumar said: “The FDA approval reflects years of scientific research and extraordinary dedication.”ScienceAlert: ““[The FDA approval] reflects years of scientific research and extraordinary dedication,” says Rolee Kumar, CEO at Marine Biomedical.”